Psychological Impact of Critical Illness

2017 ◽  
Author(s):  
O. Joseph Bienvenu ◽  
Christina Jones
Keyword(s):  
Psychological Distress ◽  
Critical Illness ◽  
Recovery Period ◽  
Psychological Impact ◽  
Anxiety Symptoms ◽  
Ptsd Symptoms ◽  
Mental Health Needs ◽  
Clinically Significant ◽  
Illness Anxiety

This chapter explores the epidemiology and range of psychological distress phenomena experienced by survivors of critical illness. The phenomena most commonly reported on are posttraumatic stress disorder (PTSD), depressive, and general (or nonspecific) anxiety symptoms. Approximately 1 in 5 critical illness survivors has clinically significant PTSD symptoms, 1 in 3 has clinically significant depressive symptoms, and 1 in 3 has clinically significant anxiety symptoms. These phenomena are associated with diminished quality of life and functioning. Risk factors include pre-critical illness anxiety and depression, in-critical illness sedative doses and nightmare-like experiences, and post–critical illness psychological distress and poor coping early in the recovery period. Given the association between critical illness and psychological distress, it is important to address survivors’ mental health needs.

scholarly journals Quality of Life, Psychological Distress, and Prognostic Awareness in Caregivers of Patients with Multiple Myeloma

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 3044-3044
Author(s):  
Elizabeth K. O'Donnell ◽  
Yael Shapiro ◽  
Omar Nadeem ◽  
Andrew J. Yee ◽  
Jacob P. Laubach ◽  
...  
Keyword(s):  
Psychological Distress ◽  
Board Of Directors ◽  
Research Funding ◽  
Ptsd Symptoms ◽  
Newly Diagnosed ◽  
Publicly Traded ◽  
Advisory Committees ◽  
Significant Depression ◽  
Clinically Significant

Abstract Background: Multiple myeloma (MM) is an incurable hematologic malignancy requiring long-term, continuous therapy. Although caregivers of MM patients play a critical role in supporting their loved ones throughout the illness course, studies examining caregiver quality of life (QOL), psychological distress, and prognostic awareness are lacking. Methods: We conducted a cross-sectional, multisite study of patients undergoing treatment with MM (excluding maintenance therapy) and their caregivers between 6/2020-3/2021. Eligible caregivers were identified by the patient as the primary caregiver and enrolled to 1 of 3 cohorts based on lines of therapy: 1) newly diagnosed receiving first-line therapy; 2) 2-3 lines; 3) ≥4 lines of therapy. Caregivers completed validated questionnaires to assess their QOL, psychological distress, and perceptions of prognosis. Patients also completed validated questions to assess their perception of prognosis. We used descriptive statistics to describe caregiver QOL, psychological distress, and perception of prognosis. We then descriptively compared psychological distress and perception of prognosis between patient and caregiver dyads. Results: We enrolled 127 caregivers of MM patients (newly diagnosed (n=43), 2-3 (n=40), and ≥ 4 lines of therapy (n=44)). Median caregiver age was 61.8 years (range 24.0-81.9); 71.7% (91/127) were female; and 68.5% (87/127) were taking care of their spouse/partner. Caregiver QOL and psychological distress did not differ by lines of therapy. The rate of clinically significant depression, anxiety, and post-traumatic stress disorder (PTSD) symptoms were 15.8% (20/127), 44.1% (56/127), and 24.4% (31/127), respectively. When examining dyads, caregivers reported higher rates of clinically significant anxiety symptoms (44.4% vs. 22.5%) compared to MM patients. Caregivers reported less clinically significant depression symptoms (15.3% vs. 24.2%) and similar rates of clinically significant PTSD symptoms (24.2% vs 25.0%). Overall, 89.6% (112/125) of caregivers reported that it is 'extremely' or 'very' important to know about the patient's prognosis and 55.6% (70/126) stated that they had received adequate information regarding the patient's prognosis. Caregivers reported that prognostic information was 'extremely' or 'very' helpful in making decisions about treatment (94.0%, 109/116), preparing for the future (88.6%, 101/114), and coping with the disease (85.2%, 98/115). Most caregivers (84.2%, 101/120), reported that the oncologist had told them the patient's cancer was incurable. In contrast, only 53.6% (59/110) of caregivers reported that they thought the patient's cancer was incurable and 37.9% (58/114) acknowledged that the patient is terminally ill. Caregiver demographics, line of therapy, QOL, and psychological distress were not associated with their perceptions of the patient's prognosis. When examined in dyads, caregivers were more likely to report that the patient is terminally ill (50.1% vs. 30.1%). There was no difference in caregivers' and patients' report that the oncologist said MM is incurable (83.3% vs. 84.2%). Conclusions: Caregivers of patients undergoing treatment for MM experience substantial psychological distress across the disease continuum, particularly anxiety. Supportive care interventions are needed to improve caregivers' QOL and to reduce their psychological distress. Although the majority of caregivers of MM patients report that knowing the patient's prognosis is extremely important and report that the oncologist told them that the patient was incurable, a significant portion of caregivers report that the patient is curable. Interventions are needed to promote effective coping and to enhance caregiver's perception of the patient's prognosis to facilitate informed-decision making. Disclosures O'Donnell: Janssen: Consultancy; Takeda: Consultancy; Oncopeptide: Consultancy; Adaptive: Consultancy; Karyopharm: Consultancy; Bristol Myer Squibb: Consultancy. Nadeem: Takeda: Consultancy; Bristol Myer Squibb: Consultancy; GSK: Consultancy; Karyopharm: Consultancy; Adaptive: Consultancy. Yee: Karyopharm: Consultancy; Sanofi: Consultancy; Oncopeptides: Consultancy; GSK: Consultancy; Takeda: Consultancy; Janssen: Consultancy; Adaptive: Consultancy; Bristol Myers Squibb: Consultancy; Amgen: Consultancy. Branagan: Sanofi-Genzyme: Consultancy, Membership on an entity's Board of Directors or advisory committees; BeiGene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees; Adaptive: Consultancy; CSL Behring: Consultancy; Pharmacyclics: Consultancy, Membership on an entity's Board of Directors or advisory committees. Anderson: AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Sanofi-Aventis: Membership on an entity's Board of Directors or advisory committees; Millenium-Takeda: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Scientific Founder of Oncopep and C4 Therapeutics: Current equity holder in publicly-traded company, Current holder of individual stocks in a privately-held company; Mana Therapeutics: Membership on an entity's Board of Directors or advisory committees. Mo: Janssen: Honoraria; Karyopharm: Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Epizyme: Consultancy; Eli Lilly: Consultancy. Munshi: Celgene: Consultancy; Oncopep: Consultancy, Current equity holder in publicly-traded company, Other: scientific founder, Patents & Royalties; Abbvie: Consultancy; Legend: Consultancy; Amgen: Consultancy; Janssen: Consultancy; Pfizer: Consultancy; Takeda: Consultancy; Karyopharm: Consultancy; Adaptive Biotechnology: Consultancy; Novartis: Consultancy; Bristol-Myers Squibb: Consultancy. Ghobrial: AbbVie, Adaptive, Aptitude Health, BMS, Cellectar, Curio Science, Genetch, Janssen, Janssen Central American and Caribbean, Karyopharm, Medscape, Oncopeptides, Sanofi, Takeda, The Binding Site, GNS, GSK: Consultancy. Sperling: Adaptive: Consultancy. Richardson: AstraZeneca: Consultancy; Protocol Intelligence: Consultancy; GlaxoSmithKline: Consultancy; Karyopharm: Consultancy, Research Funding; Secura Bio: Consultancy; Sanofi: Consultancy; Regeneron: Consultancy; Takeda: Consultancy, Research Funding; Janssen: Consultancy; Celgene/BMS: Consultancy, Research Funding; Oncopeptides: Consultancy, Research Funding; AbbVie: Consultancy; Jazz Pharmaceuticals: Consultancy, Research Funding. Raje: Caribou: Other; Janssen: Other; bluebird bio: Other; Amgen: Other; Celgene: Other; BMS: Other.

scholarly journals QOLP-04. PILOT STUDY OF A VIDEOCONFERENCE-BASED PSYCHOLOGICAL INTERVENTION FOR FAMILY CAREGIVERS OF PATIENTS WITH MALIGNANT GLIOMAS

2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii175-ii175
Author(s):  
Deborah Forst ◽  
Michelle Mesa ◽  
Emilia Kaslow-Zieve ◽  
Areej El-Jawahri ◽  
Joseph Greer ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Self Efficacy ◽  
Coping Skills ◽  
Malignant Gliomas ◽  
Anxiety Symptoms ◽  
Structured Interviews ◽  
Post Intervention ◽  
Clinically Significant ◽  
And Coping

Abstract BACKGROUND Caregivers of patients with malignant gliomas experience substantial anxiety symptoms while caring for someone with progressive neurological decline. Yet, interventions to reduce psychological distress and improve quality of life (QoL) in this caregiver population are lacking. METHODS We conducted an open pilot study evaluating feasibility and acceptability of a cognitive behavioral therapy-based intervention for caregivers of patients with malignant gliomas with clinically significant anxiety (Generalized Anxiety Disorder [GAD-7] score ≥ 5). Caregivers participated in six videoconference sessions with a mental health provider. We defined the intervention as feasible if ≥ 70% of eligible caregivers enrolled and ≥ 70% of those enrolled completed ≥ 50% of sessions. We evaluated intervention acceptability in semi-structured interviews. Caregivers completed baseline and post-intervention surveys assessing anxiety and depression symptoms (Hospital Anxiety and Depression Scale), QoL (Caregiver Oncology Quality of Life Questionnaire), caregiving burden (Caregiver Reaction Assessment), self-efficacy (Lewis Cancer Self-Efficacy Scale), and perceived coping skills (Measure of Current Status-Part A). We explored post-intervention changes using paired t-tests. RESULTS We obtained consent from 70.0% (21/30) of caregivers approached, of which 66.7% (14/21) had clinically significant anxiety and thus were eligible to participate (mean age=55.7 years, 64.3% female). Among enrolled caregivers, 71.4% (10/14) completed ≥ 50% of sessions. In semi-structured interviews, all participants found the intervention helpful and valued the ability to participate remotely via videoconference. Among caregivers who completed at least one session, 80.0% (8/10) completed all assessments and were included in analyses. Post-intervention, caregivers reported reduced anxiety symptoms (P=.02) and improved QoL (P=.03) and coping skills (P=.001). We found no significant change in depression, caregiving burden, or self-efficacy. CONCLUSION Our videoconference-based intervention is feasible and acceptable to caregivers. Participants reported significant improvements in anxiety symptoms, quality of life, and coping skills post-intervention, supporting further investigation of the intervention in a randomized controlled trial.

scholarly journals Quality of Life and Psychological Distress in Patients with Acute Myeloid Leukemia (AML)

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 2291-2291
Author(s):  
Areej El-Jawahri ◽  
Lauren Waldman ◽  
Joseph Greer ◽  
Gregory A. Abel ◽  
David P. Steensma ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Psychological Distress ◽  
Older Patients ◽  
Research Funding ◽  
Tertiary Care ◽  
Intensive Chemotherapy ◽  
Significant Depression ◽  
Linear Effects ◽  
Clinically Significant

Abstract Background: Older patients with AML face difficult treatment decisions as they can be treated either with multi-drug 'intensive' chemotherapy requiring a prolonged hospitalization, or 'non-intensive' chemotherapy. Although intensive chemotherapy is often perceived by clinicians as more burdensome, studies comparing patients' quality of life (QOL) and psychological distress while receiving these treatments are lacking. Methods: We conducted a longitudinal study of older patients (≥ 60 years) newly diagnosed with AML receiving intensive (i.e. 7+3: cytarabine/anthracycline combination) or non-intensive (i.e. hypomethylating agents) chemotherapy at two tertiary care hospitals. We assessed patient's QOL [Functional Assessment of Cancer Therapy-Leukemia], and psychological distress [Hospital Anxiety and Depression Scale [HADS]] at baseline and 2, 4, 8, 12, and 24 weeks after diagnosis. We compared the proportion of patients in each group reporting clinically significant depression or anxiety (HADS subscale cut off ≥ 7) and used mixed linear effects models to compare QOL and psychological distress longitudinally between groups. Results: We enrolled consecutive patients within 72 hours of initiating intensive (n=50) or non-intensive (n=50) chemotherapy. There were no differences in baseline QOL, depression, or anxiety symptoms between the groups. At baseline, 33.33% (33/100) and 30% (30/100) of the overall cohort reported clinically significant depression and anxiety, respectively, with no differences between groups. At 4 weeks, 41.98% (34/81) of patients in the overall cohort reported clinically significant depression, with no differences between groups. In mixed linear effects models, there were no differences in QOL (β=-0.71, SE=1.12, P=0.527), depression (β=0.24, SE=0.20, P=0.226), or anxiety (β=-0.16, SE=0.19, P=0.386) symptoms between groups over time. Conclusion: Older patients with AML receiving intensive and non-intensive chemotherapy experience similar QOL impairments and high rates of psychological distress. These findings underscore the need to develop supportive care interventions for older patients with AML, regardless of their initial treatment strategy. Disclosures Brunner: Takeda: Research Funding; Novartis: Research Funding; Celgene: Consultancy, Research Funding. Fathi:Celgene: Consultancy, Honoraria, Research Funding; Jazz: Honoraria; Boston Biomedical: Consultancy, Honoraria; Astellas: Honoraria; Agios: Honoraria, Research Funding; Seattle Genetics: Consultancy, Honoraria; Takeda: Consultancy, Honoraria. DeAngelo:ARIAD: Consultancy, Research Funding; Takeda: Honoraria; Amgen: Consultancy; Shire: Honoraria; Blueprint Medicines: Honoraria, Research Funding; Pfizer Inc: Consultancy, Honoraria; Novartis Pharmaceuticals Corporation: Consultancy, Honoraria; BMS: Consultancy; Glycomimetics: Research Funding; Incyte: Consultancy, Honoraria. Amrein:Takeda: Research Funding.

scholarly journals Changes in psychological distress and quality of life after esophageal cancer surgery: A prospective study

2020 ◽  
Author(s):  
Jeong Hye Kim ◽  
Ju Ri Jung
Keyword(s):  
Quality Of Life ◽  
Esophageal Cancer ◽  
Psychological Distress ◽  
Prospective Study ◽  
Severe Depression ◽  
Post Surgery ◽  
Eortc Qlq C30 ◽  
Clinically Significant ◽  
Eortc Qlq

Abstract Background Esophageal cancer patients experience physical and psychological difficulties after surgery. This study aimed to identify the changes in psychological distress and quality of life in patients with esophageal cancer before surgery to three months after surgery. Methods We enrolled 49 patients who were scheduled to undergo esophageal surgery at a tertiary hospital in Seoul, South Korea in this prospective study. Patients’ psychological distress and quality of life were assessed with the Korean scales HADS, EORTC QLQ-C30, and QLQ-OES18 at the pre-surgery, one-month post-surgery, and three months post-surgery. Results Moderate-to-severe depression was reported in 12.2% of patients at the pre-surgery evaluation, in 57.1% of patients one-month post-surgery, and 8.2% of patients three-months post-surgery. Moderate-to-severe depression was reported in 12.2% of patients at the pre-surgery evaluation, in 63.3% of patients one-month post-surgery, and 16.3% of patients three months post-surgery. Clinically significant, moderate changes (10–20 points) in physical functioning, insomnia, nausea and vomiting, and dyspnea, and significant, large changes (> 20) in role functioning, fatigue, pain, and appetite loss (per EORTC QLQ-C30) were reported from pre-surgery to one-month post-surgery. Clinically significant, moderate changes (10–20 points) in dysphagia and taste problems and a significant, large change (> 20) in eating difficulties (per QLQ-OES18) were reported from pre-surgery to one-month post-surgery. Conclusion One month after esophageal cancer surgery, patients demonstrated severe psychological distress and worsening quality of life.

scholarly journals Psychological impact of COVID-19 on parents of pediatric cancer patients

2020 ◽  
Author(s):  
antonella guido ◽  
elisa marconi ◽  
laura peruzzi ◽  
nicola di napoli ◽  
gianpiero tamburrini ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cancer Patients ◽  
Pediatric Cancer ◽  
Psychological Impact ◽  
High Stress ◽  
Impact Of Event Scale ◽  
Event Scale ◽  
Pediatric Cancer Patients ◽  
Clinically Significant

Background. The changes and general alarm of the current COVID-19 pandemic have amplified the sense of precariousness and vulnerability for family members who, in addition to the emotional trauma of the cancer diagnosis, add the distress and fear of the risks associated with infection. The primary objectives of the present study was to investigate the psychological impact of the COVID-19 pandemic on the parents of pediatric cancer patients, and to investigate the level of stress, anxiety, and the child’s quality of life perceived by the parents during the Covid-19 epidemic. Methods. The parents of 45 consecutive children with solid and haematological tumors were enrolled. Four questionnaires (Impact of Event Scale-Revised - IES-R ; Perceived Stress Scale - PSS; Spielberger State - Trait Anxiety Inventory - STAI-Y ; Pediatric Quality of Life Inventory - PedsQL) were administered to the parents at the beginning of the pandemic lockdown. Results. 75% of parents exhibited remarkable levels of anxiety, with 60 subjects in state scale and 45 subjects in trait scale having scores that reached and exceeded the STAI-Y cut off. The bivariate matrix of correlation (Figure 1) found a strong significant positive correlation between the IES-R and PSS scores (r = 0.55, P < 0.001). There was a positive correlations between the PSS and PedsQL (emotional needs) scale (P < 0.001) and a negative correlation between IES-R and STAI-Y (P < 0.001). Conclusion. The results confirm that parents of pediatric cancer patients have a high psychological risk for post-traumatic symptoms, high stress levels, and the presence of clinically significant levels of anxiety.

Cognitive Impairment Following Critical Illness

2014 ◽  
Author(s):  
Ramona O Hopkins ◽  
James C Jackson
Keyword(s):  
Cognitive Impairment ◽  
Critical Illness ◽  
Cognitive Impairments ◽  
Biological Mechanisms ◽  
Early Mobility ◽  
Progressive Decline ◽  
Mobility Protocols ◽  
Clinically Significant ◽  
Post Intensive Care Syndrome

Millions of individuals each year survive critical illness, many of whom will develop post-intensive care syndrome which includes new or worsening impairments in physical, psychiatric, or cognitive functioning. Cognitive impairments are common in survivors of critical illness, are often severe, and persist years after hospital discharge. Cognitive impairments improve in some patients and, in others, appear stable over time, rather display a pattern of progressive decline. Cognitive impairment contributes to clinically significant functional decrements as well as decreased quality of life. The biological mechanisms of cognitive impairment are not well defined, although numerous risk factors have been identified. As the number of ICU survivors increases, there is a growing population of patients with cognitive impairments following critical illness, underscoring the need to address cognitive impairments through prevention, treatment, and rehabilitation. Interventions to prevent or reduce the severity of cognitive impairments (i.e. sedation, delirium, and early mobility protocols) need to be investigated. Although there are very limited examples in which rehabilitation is used in ICU populations, it may hold the potential to facilitate improvements in cognition, particularly among individuals with deficits in memory, attention, and executive functioning. Despite over a decade of focused investigation, fundamental questions pertaining to cognitive impairments after critical illness exist. Research is needed on methods to proactively identify those at risk for cognitive impairment and to develop methods which will robustly prevent and improve deficits in ICU survivors.

scholarly journals A Study of Psychiatric Consequences following Road Traffic Accidents

1970 ◽  
Vol 9 (2) ◽  
pp. 1-7
Author(s):  
N Rawal ◽  
P Thapa ◽  
Y Bista
Keyword(s):  
Psychological Distress ◽  
Depressive Symptoms ◽  
Traffic Accidents ◽  
Road Traffic ◽  
Psychiatric Symptoms ◽  
Psychiatric Morbidity ◽  
Anxiety Symptoms ◽  
Ptsd Symptoms ◽  
Road Traffic Accidents ◽  
The Impact

Objectives: Psychiatric consequences are very common following RTA. The study is sought to identify the prevalence of psychiatric morbidity (e.g. depressive symptoms, anxiety symptoms and symptoms related to PTSD(Post Traumatic Stress Disorder) following injury sustained after road traffic accidents and to evaluate the relationshop between severity of injuries of  victims and psychiatric symptoms. Methods: The 102 (male=83,female=19) patients were interviewed using a questionnaire to collect the socio- demographic data, the Self Rating Questionnaire (SRQ) -Beck Depression Inventory(BDI),Beck Anxiety Inventory(BAI) and the Impact of Event Scale -Revised (IES-R). Patients were prospectively followed up for 1 month. Patients were aged between 20-69 years. The impact of injury was assessed by ISS (Injury Severity Scale) and ABI (Abbreviated injury Scale). Results:The mean age was 33.93 years (range 20-69). Overall, the prevalence rate o of Anxiety symptoms-19.6%, depressive symptoms-21.6% and PTSD symptoms-35.3%. Females had a higher rate of PTSD symptoms 52.6% (n = 10), compared to the males 31.3% (n=26). The majority of those with PTSD (47.2%) were young, 20 - 29 years. The samples showed maximum symptoms of PTSD in first week 93.1% followed by depressive symptoms 51% and then anxiety symptoms30.4%. The symptoms gradually reduced in the fourth week to PTSD - 35.3%, depression- 21.6% and anxiety-19.6%. The study also showed higher scales of psychiatric symptoms in major injuries in comparison to minor injuries showing direct correlation of psychiatric morbidity with severity of injury. Conclusion: Psychiatric symptoms are frequent and severe after major injuries and less severe after minor RTA. Psychopathology following injury is a frequent and persistent occurrence. Early information and advice might reduce psychological distress and symptoms. Early information and advice might reduce psychological distress and symptoms. DOI: http://dx.doi.org/10.3126/mjsbh.v9i2.5017 Medical Journal of Shree Birendra Hospital Vol.9(2) 2010: 1-7

scholarly journals Impact of the Worst School Experiences in Students: A Retrospective Study on Trauma

2015 ◽  
Vol 25 (62) ◽  
pp. 343-352 ◽  
Author(s):  
Paloma Pegolo de Albuquerque ◽  
Lucia C. A. Williams
Keyword(s):  
Retrospective Study ◽  
University Students ◽  
School Violence ◽  
Traumatic Event ◽  
Psychological Impact ◽  
School Experiences ◽  
Ptsd Symptoms ◽  
Cognitive Difficulties ◽  
School Victimization ◽  
Clinically Significant

AbstractThe literature indicates damage to students' mental health in cases of school violence. The aim of this retrospective study was to evaluate the psychological impact of school victimization in university students, and to analyze the association between PTSD symptoms and variables related to school victimization. 691 University students responded to the Portuguese version of the Student Alienation and Trauma Survey (SATS). Clinically significant scores in the subscales ranged from 4.7% (somatic symptoms) to 20% (hypervigilance), with frequent symptoms described in the literature resulting from school victimization, such as depression, hopelessness, cognitive difficulties, and traumatic event recollection. Additionally, 7.8% of participants presented PTSD symptoms after suffering their "worst school experience". Associations were found between PTSD symptoms and the level of distress after the experience, as well as the perceived benefits after the event, and duration. The results confirm the potential detrimental effects of school victimization, and may be useful to further investigations on this topic.

scholarly journals Increased Psychological Distress during COVID-19 and Quarantine in Ireland: A National Survey

2020 ◽  
Vol 9 (11) ◽  
pp. 3481 ◽  
Author(s):  
Tom Burke ◽  
Anna Berry ◽  
Laura K. Taylor ◽  
Owen Stafford ◽  
Eddie Murphy ◽  
...  
Keyword(s):  
Psychological Distress ◽  
Online Survey ◽  
Illness Perceptions ◽  
Psychological Impact ◽  
Well Being ◽  
Cross Sectional ◽  
Aging Parents ◽  
Symptoms Of Depression ◽  
Global Pandemic ◽  
Clinically Significant

Background: The emergence of the coronavirus pneumonia (COVID-19) resulted in a global pandemic. The psychological impact of an epidemic is multifaceted and acute, with long-term consequences. Methods: A cross-sectional online survey-based design was employed, assessing the psychological impact of COVID-19 on members of the Irish public during the quarantine period of COVID-19 in Ireland. Participants were invited to complete the Depression, Anxiety, and Stress Scale-21 (DASS-21) retrospectively (prior to quarantine) and during the quarantine period, as well as measures of illness perceptions, well-being, and a bespoke measure (the Effects of COVID Questionnaire, ECQ), which assessed perceptions of COVID-related stresses associated with personal concerns, caring for children, caring for aging parents, as well as gratitude. Results: A total of n = 1620 entered the survey platform, with a total of n = 847 surveys completed by members of the Irish public. Entry into COVID-19 quarantine was associated with significant increases in clinically significant symptoms of depression, stress, and anxiety. The ECQ reliably assessed a range of COVID-19-related stresses and had large and significant correlations with the DASS-21. Conclusions: The COVID-19 quarantine was associated with stresses and significant increases in symptoms of depression, anxiety, and stress in a national Irish cohort. The public require increased access to mental health services to meet this increase in COVID-19-related psychological distress.

scholarly journals Dementia-Related Anxiety and General Illness Anxiety Differ Based on Familial Exposure to Persons With Dementia

2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 283-284
Author(s):  
Erika Fenstermacher ◽  
Alexandria Ebert ◽  
Natalie Shook ◽  
Jerin Lee ◽  
Jenna Wilson ◽  
...  
Keyword(s):  
Family Member ◽  
Online Survey ◽  
Critical Role ◽  
Psychological Impact ◽  
Specific Form ◽  
Mechanical Turk ◽  
Dementia Worry ◽  
Illness Anxiety ◽  
Amazon's Mechanical Turk

Abstract Dementia-related anxiety is a specific form of illness anxiety that has been associated with familial exposure to persons with dementia (FMwDs). However, it is unknown whether FMwDs is specifically associated with dementia-related anxiety or whether it is also related to general illness anxiety, which has broader health implications. Furthermore, the level of exposure to family members with dementia may matter. Thus, we examined whether level of familial exposure to dementia was related to general illness anxiety and dementia-related anxiety. Participants (N = 401) aged 18-76 years (M = 39) recruited through Amazon’s Mechanical Turk completed an online survey. Dementia exposure was split into three levels: (1) not knowing a friend/family member with dementia (55.2%); (2) knowing a family member with dementia (33.9%); and (3) providing care for a family member with dementia (10.9%). Familial exposure to dementia was related to both general illness anxiety and dementia-related anxiety. Participants who provided care for FMwDs had significantly higher levels of illness anxiety than both people who had a FMwD and people who did not (ps &lt; .001). Similarly, participants who provided care for FMwDs had significantly higher levels of dementia-related anxiety than participants who did not have a FMwD (p &lt; .01). Caregivers play a critical role in the quality of life of those with dementia, however it is clear that the potential psychological impact of such work is pervasive. This study provides a foundation to explore differences between illness anxiety and dementia worry, and examine interventions to reduce anxiety among caregivers.

Sign in / Sign up

Export Citation Format

Share Document